Given these promising preclinical results, the same group initiated a phase I/II clinical trial in 2018 to evaluate the effects of the systemic administration of a fully human L19-TNF immunocytokine in patients with grade III or IV and IDH1 wild-type gliomas undergoing their first relapse (NCT03779230). Here, TNF is linked to central nervous system cancer.